Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen.
Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen.
复制标题
合成 D(-) 青霉胺治疗类风湿性关节炎。
DOI：
10.1136/ard.34.5.416
复制
发表时间：
1975
影响因子：
27.4
通讯作者：
D. Zutshi
中科院分区：
文献类型：
--
作者：
A. Dixon;J. Davies;T. Dormandy;E. Hamilton;P. Holt;R. M. Mason;M. Thompson;J. Weber;D. Zutshi
每日600 mg和1200 mg D（-）青霉胺的剂量上级优于类风湿关节炎的标准治疗方案。在接受治疗的患者组中，较高剂量并未产生显著更大的治疗获益，尽管个别患者有时改善更多。皮疹、血恶液质和退出试验的频率随剂量增加而增加。得出结论，D（-）青霉胺是一种有用的治疗方法，日剂量应尽可能低，仅应在不频繁的时间间隔内增加，并适当考虑进一步改善不良反应风险增加的可能性。
Doses of 600 mg and 1200 mg of D(-)penicillamine daily were superior to a standard regimen of therapy in rheumatoid arthritis. The higher dose did not produce significantly greater therapeutic benefit in the group of patients so treated, although individual patients sometimes improved more. The frequency of rashes, blood dyscrasias, and withdrawals from the trial increased withe dosage. It is concluded that D(-)penicillamine is a useful treatment that the daily dose should be as low as possible, and that it should be increased at infrequent intervals only, with due regard to the likelihood of further improvement in relation to an increased risk of adverse reactions.